Cardionovum® Begins Clinical Study Of APERTO® Drug Coated Balloon (DCB), Designed For Long-Term Prevention Of Shunt Restenosis In Hemodialysis Patients
CEO Dr. Michael Orlowski is considered the pioneer of Drug Coated Balloons, having invented the first CE-marked DCB for the cardiovascular market in 2007
BONN, Germany--(BUSINESS WIRE)--Cardionovum GmbH announced today that it has initiated a 150-patient clinical study of its novel paclitaxel-releasing, high-pressure shunt balloon dilatation catheter, APERTO®. The study aims to sustain the highly promising and significant first clinical evidence for APERTO.
Regardless of whether it is created as an arterio-venous fistula (AVF) or as a shunt graft, hemodialysis shunt patency is threatened by restenosis, which is the number-one cause of hemodialysis shunt failure and a dreaded complication in the treatment of hemodialysis-dependent, end-stage renal disease patients. Short-cutting the arterial and venous vascular system to create a hemodialysis shunt results in hemodynamic pressure and blood flow gradients that are crucial to enable hemodialysis but which induce as a downside the formation of neo-intimal hyperplasia and stenosis. As the patency of the shunt is essential for the survival of the patients, the suppression of neo-intimal hyperplasia is the logical way to lower the frequency of the necessary shunt interventions and prolong overall hemodialysis shunt patency.
Hemodialysis shunt stenosis treatment with Cardionovum’s novel APERTO paclitaxel-releasing, high-pressure balloon dilatation catheter adds an unparalleled anti-inflammatory and anti-proliferative therapeutic effect to the conventional, purely mechanical angioplasty procedure, which — despite being ineffective in restenosis prevention — is currently widely used to treat hemodialysis vessel stenosis.
“The application of APERTO promises a substantial reduction of hemodialysis shunt restenosis for a prolonged dialysis access survival. This means less shunt re-interventions for a better patient life quality,” said William Loan, MD, Principal Study Investigator at the National Vascular Hospital, Belfast, Ireland.
The drug paclitaxel, along with the highly effective novel “INTENSE” drug release composition on the APERTO balloon surface, cannot be compared with any of the conventional DCB drug coatings that are marketed, for example, for treating peripheral artery lesions. APERTO’s “INTENSE” drug coating is designed for the treatment of the complex restenotic and scarred hemodialysis shunt tissue and prolongs significantly the interval until the unavoidable re-intervention. It has the potential to fully replace the conventional, purely mechanical angioplasty procedure, whose mode of action catalyzes excessive mechanical stress with consecutive disruption of the vessel intima and media, as well as tension on the adventitia. The purely mechanical — and traumatic — treatment triggers the migration and proliferation of fibroblasts, myofibroblasts, smooth muscle cells and further contributes to the development of consecutive neo-intimal hyperplasia.
Early clinical data with APERTO DCB have shown that the negative cycle of repeated, purely mechanical shunt treatments are reduced significantly by the pro-healing effect of APERTO DCB.
“Cardionovum is focused on developments of truly innovative cardiovascular medical devices: specifically, next-generation, drug-releasing balloon and stent technologies. APERTO follows our commercialization of peripheral and coronary DCB devices LEGFLOW® and RESTORE®, which represent another novel third-generation DCB technology, SAFEPAX,” said Michael Orlowski, MD, CEO.
About Cardionovum
Cardionovum’s mission and vision is to continuously explore new therapeutic pathways to improve and extend the life quality of patients diagnosed with cardiovascular disease. Based on its breakthrough and proprietary drug transfer platform technology, Cardionovum has developed and is commercializing in Europe clinically advanced medical therapies that are designed to improve upon current patient treatment standards for drug-eluting stents and drug-eluting balloons to treat coronary and peripheral artery disease. Dr. Michael Orlowski is considered as the pioneer of drug coated balloon (DCB) catheters, as he was the first to obtain CE mark approval for a DCB, which was introduced into the cardiovascular market in 2007. He continues to be a visionary innovator by developing and introducing additional groundbreaking treatment options.
About APERTO®
APERTO® is the first paclitaxel-releasing, high-pressure shunt balloon dilatation catheter for the treatment of stenosis and prolonged prevention of stenosis in hemodialysis shunts.
NOTICE: Cardionovum’s products are not available for sale in the United States.
Contacts
Cardionovum
Dr. Michael Orlowski, +49 (0) 228 - 90 97 22 69
CEO
Help employers find you! Check out all the jobs and post your resume.
BONN, Germany--(BUSINESS WIRE)--Cardionovum GmbH announced today that it has initiated a 150-patient clinical study of its novel paclitaxel-releasing, high-pressure shunt balloon dilatation catheter, APERTO®. The study aims to sustain the highly promising and significant first clinical evidence for APERTO.
Regardless of whether it is created as an arterio-venous fistula (AVF) or as a shunt graft, hemodialysis shunt patency is threatened by restenosis, which is the number-one cause of hemodialysis shunt failure and a dreaded complication in the treatment of hemodialysis-dependent, end-stage renal disease patients. Short-cutting the arterial and venous vascular system to create a hemodialysis shunt results in hemodynamic pressure and blood flow gradients that are crucial to enable hemodialysis but which induce as a downside the formation of neo-intimal hyperplasia and stenosis. As the patency of the shunt is essential for the survival of the patients, the suppression of neo-intimal hyperplasia is the logical way to lower the frequency of the necessary shunt interventions and prolong overall hemodialysis shunt patency.
Hemodialysis shunt stenosis treatment with Cardionovum’s novel APERTO paclitaxel-releasing, high-pressure balloon dilatation catheter adds an unparalleled anti-inflammatory and anti-proliferative therapeutic effect to the conventional, purely mechanical angioplasty procedure, which — despite being ineffective in restenosis prevention — is currently widely used to treat hemodialysis vessel stenosis.
“The application of APERTO promises a substantial reduction of hemodialysis shunt restenosis for a prolonged dialysis access survival. This means less shunt re-interventions for a better patient life quality,” said William Loan, MD, Principal Study Investigator at the National Vascular Hospital, Belfast, Ireland.
The drug paclitaxel, along with the highly effective novel “INTENSE” drug release composition on the APERTO balloon surface, cannot be compared with any of the conventional DCB drug coatings that are marketed, for example, for treating peripheral artery lesions. APERTO’s “INTENSE” drug coating is designed for the treatment of the complex restenotic and scarred hemodialysis shunt tissue and prolongs significantly the interval until the unavoidable re-intervention. It has the potential to fully replace the conventional, purely mechanical angioplasty procedure, whose mode of action catalyzes excessive mechanical stress with consecutive disruption of the vessel intima and media, as well as tension on the adventitia. The purely mechanical — and traumatic — treatment triggers the migration and proliferation of fibroblasts, myofibroblasts, smooth muscle cells and further contributes to the development of consecutive neo-intimal hyperplasia.
Early clinical data with APERTO DCB have shown that the negative cycle of repeated, purely mechanical shunt treatments are reduced significantly by the pro-healing effect of APERTO DCB.
“Cardionovum is focused on developments of truly innovative cardiovascular medical devices: specifically, next-generation, drug-releasing balloon and stent technologies. APERTO follows our commercialization of peripheral and coronary DCB devices LEGFLOW® and RESTORE®, which represent another novel third-generation DCB technology, SAFEPAX,” said Michael Orlowski, MD, CEO.
About Cardionovum
Cardionovum’s mission and vision is to continuously explore new therapeutic pathways to improve and extend the life quality of patients diagnosed with cardiovascular disease. Based on its breakthrough and proprietary drug transfer platform technology, Cardionovum has developed and is commercializing in Europe clinically advanced medical therapies that are designed to improve upon current patient treatment standards for drug-eluting stents and drug-eluting balloons to treat coronary and peripheral artery disease. Dr. Michael Orlowski is considered as the pioneer of drug coated balloon (DCB) catheters, as he was the first to obtain CE mark approval for a DCB, which was introduced into the cardiovascular market in 2007. He continues to be a visionary innovator by developing and introducing additional groundbreaking treatment options.
About APERTO®
APERTO® is the first paclitaxel-releasing, high-pressure shunt balloon dilatation catheter for the treatment of stenosis and prolonged prevention of stenosis in hemodialysis shunts.
NOTICE: Cardionovum’s products are not available for sale in the United States.
Contacts
Cardionovum
Dr. Michael Orlowski, +49 (0) 228 - 90 97 22 69
CEO
Help employers find you! Check out all the jobs and post your resume.